[ad_1] RT @RetinalPhys: Retinal OCT Biomarkers for Clinicians and Clinical Researchers: Recent studies may yield meaningful prognostic and treatme… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] OIS Podcast Episode #270: KOLs Speak Out on the Future of Gene Therapy https://t.co/nXMnR91Btg via @YouTube [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Given recent clinical trial results in geographic atrophy/dry AMD, there has been great interest in our review of complement inhibition as a therapeutic strategy in retinal disorders #retina #eye #macula #AMD #clinicaltrials https://t.co/z4YaBgcE1n [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @RetinalPhys: Accessing the suprachoroidal space can bypass the ILM barrier and enhance delivery of drug to the retina, RPE, and choroid… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Just published…With ~50% patients not requiring additional treatment for 9 months after the last CLS-TA treatment, demonstrates the potential for durability with the suprachoroidal platform & small molecule suspensions such as CLS-TA. #retina #eyes https://t.co/JRiSW8r5ht [ad_2] Source by Thomas Ciulla, MD, MBA Return to …

[ad_1] Looking forward to participating in this week’s Wet AMD & DME Drug Development Summit: #eyes #ophthalmology #retina #macula #diabetes #diabeticretinopathy #AMD #maculardegeneration #drugdevelopment #healthcare #biotech #biotechnology #clinicalresearch https://t.co/z903ngBrXO [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Just published: OCT plays a key role in retina care & clinical trials, but OCT biomarkers can show limited correlation… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.